BioCentury | Mar 26, 2001
Company News

Tepnel management update

...Manchester, U.K. Business: Diagnostics/Imaging Appointed: Benjamin Matzilevich as CEO, formerly VP of business development at CN Biosciences Inc. WIR...
BioCentury | Mar 21, 2001
Company News

Tepnel appoints new CEO

...analysis company Tepnel Life Sciences (LSE:TED). He was formerly vice president of business development at CN Biosciences...
BioCentury | Oct 2, 2000
Company News

Prolinx, CN Biosciences deal

...sciences research. Prolinx retains all rights to commercial applications of Versalinx. Prolinx Inc., Bothell, Wash. CN Biosciences Inc....
BioCentury | Nov 15, 1999
Company News

Nanogen board of directors update

...technology Appointed: Val Buonaiuto, senior advisor to Hitachi Instruments Inc.; and Stelios Papadopoulos, CEO of CN Biosciences Inc. WIR...
BioCentury | Jan 25, 1999
Clinical News

N-monomethyl-L-arginine: Phase II

...target in this indication. L-NMMA is a research reagent sold by Clinalfa, a division of CN Biosciences Inc....
BioCentury | Dec 14, 1998
Company News

CN Biosciences, Merck KGaA deal

...affiliate acquired CNBI for $146 million in cash. CNBI’s San Diego facility will be retained. CN Biosciences Inc....
BioCentury | Mar 9, 1998
Company News

Chromagen, CN Biosciences deal

...Chromagen. CNBI made an undisclosed equity investment in Chromagen. Chromagen Inc. , San Diego, Calif. CN Biosciences Inc....
BioCentury | Dec 8, 1997
Company News

CN Biosciences, Stressgen deal

...years SSB's signal transduction reagents. SSB retains the right to directly market the products worldwide. CN Biosciences Inc....
BioCentury | Dec 8, 1997
Company News

CN Biosciences, Novagen Inc. deal

...and purification systems for research. CNBI expects Novagen's 1997 sales to be about $4 million. CN Biosciences Inc....
BioCentury | Mar 17, 1997
Finance

OVERHANG

...OVERHANG Follow-ons Shares Price at filing ArQule (ARQL) 1.6 million $19.50 CN Biosciences (CNBI) 90,000 $15.00 Guilford...
Items per page:
1 - 10 of 14
BioCentury | Mar 26, 2001
Company News

Tepnel management update

...Manchester, U.K. Business: Diagnostics/Imaging Appointed: Benjamin Matzilevich as CEO, formerly VP of business development at CN Biosciences Inc. WIR...
BioCentury | Mar 21, 2001
Company News

Tepnel appoints new CEO

...analysis company Tepnel Life Sciences (LSE:TED). He was formerly vice president of business development at CN Biosciences...
BioCentury | Oct 2, 2000
Company News

Prolinx, CN Biosciences deal

...sciences research. Prolinx retains all rights to commercial applications of Versalinx. Prolinx Inc., Bothell, Wash. CN Biosciences Inc....
BioCentury | Nov 15, 1999
Company News

Nanogen board of directors update

...technology Appointed: Val Buonaiuto, senior advisor to Hitachi Instruments Inc.; and Stelios Papadopoulos, CEO of CN Biosciences Inc. WIR...
BioCentury | Jan 25, 1999
Clinical News

N-monomethyl-L-arginine: Phase II

...target in this indication. L-NMMA is a research reagent sold by Clinalfa, a division of CN Biosciences Inc....
BioCentury | Dec 14, 1998
Company News

CN Biosciences, Merck KGaA deal

...affiliate acquired CNBI for $146 million in cash. CNBI’s San Diego facility will be retained. CN Biosciences Inc....
BioCentury | Mar 9, 1998
Company News

Chromagen, CN Biosciences deal

...Chromagen. CNBI made an undisclosed equity investment in Chromagen. Chromagen Inc. , San Diego, Calif. CN Biosciences Inc....
BioCentury | Dec 8, 1997
Company News

CN Biosciences, Stressgen deal

...years SSB's signal transduction reagents. SSB retains the right to directly market the products worldwide. CN Biosciences Inc....
BioCentury | Dec 8, 1997
Company News

CN Biosciences, Novagen Inc. deal

...and purification systems for research. CNBI expects Novagen's 1997 sales to be about $4 million. CN Biosciences Inc....
BioCentury | Mar 17, 1997
Finance

OVERHANG

...OVERHANG Follow-ons Shares Price at filing ArQule (ARQL) 1.6 million $19.50 CN Biosciences (CNBI) 90,000 $15.00 Guilford...
Items per page:
1 - 10 of 14